NLS Biotech Business

The two companies have entered into a strategic partnership featuring customized development services for Xdarzane, Xbrane's biosimilar candidate referencing Darzalex (daratumumab).

The Swedish spatial biology startup Haga Bioscience has closed a USD 2.3 million oversubscribed seed financing round bringing total funding, including pre-seed financing, to approximately USD 3 million.

Camurus has entered a global collaboration and license agreement with Eli Lilly and Company to develop long-acting incretin-based therapies for cardiometabolic diseases using its FluidCrystal technology platform.

The agreement for distribution and commercialization of Pepaxti in Central and Eastern Europe addresses a market potential of approximately SEK 150 million and enables potential sales uptake in this region earlier than previously planned, the company states.

Hansa Biopharma and SERB S.A. have announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.

BioArctic’s partner Eisai has announced that the FDA has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi Iqlik, as a starting dose for the treatment of early Alzheimer’s disease.